About C2i Genomics
C2i Genomics is a company based in New York (United States) founded in 2019 was acquired by Veracyte in January 2024.. C2i Genomics has raised $112 million across 2 funding rounds from investors including ARE, Veracyte and Driehaus. C2i Genomics has completed 1 acquisition, including QnA DX. C2i Genomics offers products and services including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay. C2i Genomics operates in a competitive market with competitors including Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others.
- Headquarter New York, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Veracyte, Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of C2i Genomics
C2i Genomics offers a comprehensive portfolio of products and services, including Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Test for thyroid cancer detection using genomic sequencing.
Assay for prostate cancer risk assessment via genomics.
Tool for breast cancer prognosis using gene expression.
Test for bladder cancer monitoring with AI integration.
Platform for detecting residual cancer via whole-genome sequencing.
Unlock access to complete
Unlock access to complete
Funding Insights of C2i Genomics
C2i Genomics has successfully raised a total of $112M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $100.0M
-
First Round
First Round
(22 May 2020)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series B - C2i Genomics | Valuation | Casdin Capital | |
| May, 2020 | Amount | Series A - C2i Genomics | Valuation | Casdin Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in C2i Genomics
C2i Genomics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Veracyte and Driehaus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Founded Year | Domain | Location | |
|
Venture capital firm offering funding and tools for startups in technology and investment sectors.
|
Founded Year | Domain | Location | |
|
Tech and life Science focused early stage VC firm investing in the US
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by C2i Genomics
C2i Genomics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include QnA DX. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Standalone clinical diagnostic laboratory services are operated in Cambridge.
|
2018 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - C2i Genomics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
C2i Genomics Comparisons
Competitors of C2i Genomics
C2i Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GRAIL, Natera, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Circulating tumor DNA is screened for early cancer detection.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on C2i Genomics
Frequently Asked Questions about C2i Genomics
When was C2i Genomics founded?
C2i Genomics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is C2i Genomics located?
C2i Genomics is headquartered in New York, United States. It is registered at New York, New York, United States.
Is C2i Genomics a funded company?
C2i Genomics is a funded company, having raised a total of $112M across 2 funding rounds to date. The company's 1st funding round was a Series A of $12M, raised on May 22, 2020.
What does C2i Genomics do?
C2i Genomics was founded in 2019 and is based in New York, United States. Operations focus on the biotechnology sector, where liquid biopsy services are delivered for monitoring patients after cancer surgery. Genetic changes across tumors are detected through a specialized tool. Thousands of data points from routine blood tests are compared to tumor tissue sequences and whole-genome data using bioinformatics and AI methods.
Who are the top competitors of C2i Genomics?
C2i Genomics's top competitors include Guardant Health, GRAIL and Strand Life Sciences.
What products or services does C2i Genomics offer?
C2i Genomics offers Afirma Genomic Sequencing Classifier, Decipher Prostate Genomic Classifier, Prosigna Breast Cancer Assay, Decipher Bladder Genomic Classifier, and Veracyte MRD Assay.
How many acquisitions has C2i Genomics made?
C2i Genomics has made 1 acquisition, including QnA DX.
Who are C2i Genomics's investors?
C2i Genomics has 11 investors. Key investors include ARE, Veracyte, Driehaus, Gordon Asset Management, and Casdin Capital.